Combination therapy improves tumor response in HER2-positive breast cancer patients

[News]

A combination of lapatinib, trastuzumab and paclitaxel significantly improved tumor response rates than either agent alone among patients with HER2-positive breast cancers, according to data presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12.

More... (http://www.news-medical.net/news/20101213/Combination-therapy-improves-tumor-response-in-HER2-positive-breast-cancer-patients.aspx)